

*This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu).*

ELICITATION AND CHARACTERIZATION OF MONOCLONAL ANTI-  
IDIOTYPIC ANTIBODIES REACTIVE WITH THE LIGAND BINDING  
SITES OF MONOCLONAL KININ ANTIBODIES

Robert J. Carlin

Submitted to the faculty of the Graduate School  
in partial fulfillment of the requirements  
for the degree  
Doctor of Philosophy, in the Medical Sciences Program,  
Pharmacology Section, Indiana University.

May, 1992

Accepted by the Graduate Faculty, Indiana University,  
in partial fulfillment of the requirements of the degree  
Doctor of Philosophy.

*Charles E. Ody*

Dr. Charles E. Ody, Chairman

*Talmage R. Bosin*

Dr. Talmage R. Bosin

*Edward H. Goh*

Dr. Edward H. Goh

*Bruce J. Martin*

Dr. Bruce J. Martin

*Joseph A. Near*

Dr. Joseph A. Near

*John B. Watkins III*

Dr. John B. Watkins III

Date of Oral  
Examination

5/8/92

## Abstract

In an attempt to generate monoclonal antibodies reactive with B2 bradykinin receptors, monoclonal anti-idiotypic antibodies (mAB2s) were elicited against monoclonal kinin antibodies (mAB1s) previously shown to have a binding specificity similar to a B2 bradykinin receptor (Biochem Pharmacol 40:245-251, 1990). Two separate fusions were performed using spleen cells from mice immunized with one of two mAB1s. Five clones were identified from each fusion using an ELISA which tested for bradykinin inhibition of hybridoma tissue culture supernatant binding to a plate coated with mAB1 Fab. Cross-reactivities of the mAB2s with mAB1s were evaluated by examining the ability of four mAB1s with similar kinin binding specificities to inhibit mAB2 binding to a plate coated with mAB1 Fab. The ten mAB2s cross-reacted to varying degrees with the mAB1s. Five of the mAB2s reacted equally well with all four mAB1s. In addition, the abilities of these mAB2s to inhibit the binding of biotinylated-kallidin to the four mAB1s was tested. In each case the mAB2s inhibited biotinylated-kallidin binding. We therefore conclude that the interaction of the mAB2s with the mAB1s occurs with an idiotope in, or in some way related to, the ligand binding sites of the mAB1s. These results are consistent with the mAB2s mimicking the epitope of bradykinin that is recognized by these kinin antibodies. Therefore, these mAB2s may be

mAB2  $\beta$  type "internal image" anti-idiotypic antibodies.

In order to confirm the "internal image" nature of the mAB2s, experiments were performed to demonstrate their biological activities on B2 bradykinin receptors in PC12 cells. The assay tested the abilities of the mAB2s to mimic, or to inhibit, bradykinin induced increases in cytosolic calcium. The mAB2s did not exhibit agonist or antagonist activities in this system. However, because there have been no reports of any antibodies reactive with BK receptors that either mimic or inhibit bradykinin's effects on PC12 cells, it is possible that this bioassay may not be suitable for the detection of such antibodies.

## Table of Contents

|   |      |
|---|------|
| Acknowledgements.....   | iii  |
| Abbreviations.....  | v    |
| Index of Tables and Figures.....                                      | xiii |
| Abstract.....   | xv   |
| I. Introduction and Literature Review.....                            | 1    |
| A. Introduction.....  | 2    |
| B. Kallikrein-Kinin System.....                                       | 3    |
| i. Overview.....  | 3    |
| ii. Kallikreins.....  | 6    |
| iii. Kininogens.....  | 7    |
| iv. Kinins.....   | 8    |
| v. Kininases.....   | 11   |
| vi. Receptors.....  | 12   |
| C. Anti-idiotypic Antibodies.....                                     | 14   |
| i. Network Theory.....  | 14   |
| ii. Internal Image Concept.....                                       | 18   |
| iii. Anti-idiotypic Antibodies in<br>Receptor Studies.....            | 25   |
| iv. Anti-idiotypic Antibodies Reactive<br>with Peptide Receptors..... | 26   |
| a. Insulin.....   | 26   |
| b. Thyrotropin.....   | 30   |
| c. $\beta$ -Endorphin.....  | 31   |
| d. Glucagon.....  | 33   |
| e. Prolactin.....   | 33   |
| f. Vasopressin.....   | 34   |

|     |  |    |
|-----|--|----|
| g.  | Substance P.....   | 36 |
| h.  | Angiotensin II.....  | 37 |
| i.  | Corticotropin Releasing Factor.  | 39 |
| j.  | Atrial Natriuretic Factor.....   | 40 |
| k.  | Growth Hormone.....  | 40 |
| l.  | Thyrotropin Releasing Hormone..  | 42 |
| m.  | Bradykinin.....  | 43 |
| D.  | Production and Detection of Anti-<br>idiotypic Antibodies.....   | 44 |
|     | i. Anti-idiotypic Antibody: Monoclonal<br>vs. Polyclonal.....  | 44 |
|     | ii. Antigen: Monoclonal vs. Polyclonal..   | 47 |
|     | iii. Form of the Antigen.....  | 49 |
|     | iv. Animal Selection and Immunization<br>Schedules.....  | 50 |
|     | v. Assays for Anti-idiotypic<br>Antibodies.....  | 52 |
|     | a. Overview.....   | 52 |
|     | b. AB2 Interaction with AB1.....   | 53 |
|     | c. AB2 Interaction with Receptor..   | 55 |
|     | d. AB2 biological Effect.....  | 56 |
| E.  | Overview of the Current Project.....   | 58 |
| II. | Elicitation of a Polyclonal Rabbit AB2<br>Reactive with a Bradykinin Receptor-<br>Like Activity Solubilized From Bovine<br>Uterine Myometrium..... | 60 |
| A.  | Introduction.....  | 61 |
| B.  | Materials and Methods.....   | 61 |
|     | i. Materials.....  | 61 |
|     | ii. Immunization of Rabbit.....  | 63 |

|       |  |    |
|-------|--|----|
| iii.  | Purification of Polyclonal Antiserum.....  | 63 |
| iv.   | Screening of Purified Polyclonal Rabbit AB2 on Intact mAB1s.....   | 64 |
| v.    | Preparation of mAB1 Fab Fragments...   | 65 |
| vi.   | Screening of Purified Polyclonal Rabbit AB2 on mAB1 Fabs.....  | 66 |
| vii.  | Comparison of Intact mAB1 vs. mAB1 Fab Coating Efficiency.....   | 67 |
| viii. | Preparation of Immunoaffinity Columns.....   | 68 |
| ix.   | Determination of Polyclonal Rabbit AB2 Cross-Reactivity with the B2 BK Receptor.....                                 | 69 |
| C.    | Results.....   | 70 |
| i.    | Screening of Purified Polyclonal Rabbit AB2 on Intact mAB1s.....   | 70 |
| ii.   | Screening of Purified Polyclonal Rabbit AB2 on mAB1 Fabs.....  | 73 |
| iii.  | Comparison of Intact mAB1 vs. mAB1 Fab Coating Efficiency.....   | 73 |
| iv.   | Determination of Polyclonal Rabbit AB2 Cross-Reactivity with the B2 BK Receptor.....                                 | 78 |
| D.    | Discussion.....  | 78 |
| i.    | Introduction.....  | 78 |
| ii.   | Polyclonal AB2 Screening ELISA and AB2 Affinity Column Experiments.....  | 81 |
| iii.  | Development of Screening Assay for mAB2s.....  | 83 |
| iv.   | Comparison of Intact mAB1 vs. mAB1 Fab Coating Efficiency.....   | 84 |
| III.  | Elicitation and Characterization of mAB2s Reactive with the Ligand Binding Sites of Monoclonal Kinin Antibodies..... | 86 |



|    |  |     |
|----|--|-----|
| A. | Introduction.....  | 87  |
| B. | Materials and Methods.....   | 88  |
|    | i. Materials.....  | 88  |
|    | ii. Preparation of Immunogens.....   | 89  |
|    | iii. Immunization of Mice.....   | 90  |
|    | iv. Cell Culture Media.....  | 91  |
|    | v. Fusions.....  | 91  |
|    | vi. Screening of Hybridoma Tissue<br>Culture Supernatants.....   | 93  |
|    | vii. Screening of Polyclonal Mouse<br>Antisera.....  | 97  |
|    | viii. Isotyping.....   | 97  |
|    | ix. Inhibition of mAB2 Binding to mAB1<br>Fab Fragments by Intact Monoclonal<br>Kinin Antibodies.....    | 98  |
|    | x. Inhibition of Biotinylated-kallidin<br>Binding to Intact Monoclonal Kinin<br>Antibodies by mAB2s..... | 101 |
| C. | Results.....   | 105 |
|    | i. Screening of Polyclonal Antisera....  | 105 |
|    | ii. Initial Screening of Fusions.....  | 106 |
|    | iii. Isotyping.....  | 106 |
|    | iv. Inhibition of mAB2 Binding to mAB1<br>Fab Fragments by Intact Monoclonal<br>Kinin Antibodies.....    | 106 |
|    | v. Inhibition of Biotinylated-kallidin<br>Binding to Intact Monoclonal Kinin<br>Antibodies by mAB2s..... | 120 |
| D. | Discussion.....  | 132 |
|    | i. Screening of Polyclonal Antisera....  | 132 |
|    | ii. Screening of Hybridoma Tissue<br>Culture Supernatants.....   | 134 |

|      |   |     |
|------|---|-----|
| iii. | Inhibition of mAB2 Binding to mAB1 Fab Fragments by Intact Monoclonal Kinin Antibodies.....     | 135 |
| iv.  | Inhibition of Biotinylated-kallidin Binding to Intact Monoclonal Kinin Antibodies by mAB2s..... | 137 |
| v.   | Summary.....  | 142 |
| IV.  | Testing for mAB2 Biological Effects.....  | 144 |
| A.   | Introduction.....   | 145 |
| i.   | Bradykinin Induced Increase in Cytosolic Calcium in PC12 Cells.....                             | 145 |
| ii.  | Fura-2.....   | 146 |
| iii. | Testing of mAB2s.....   | 147 |
| B.   | Materials and Methods.....  | 148 |
| i.   | Materials.....  | 148 |
| ii.  | Cell Culture.....   | 148 |
| iii. | Loading Cells with Fura-2 AM.....   | 149 |
| iv.  | Bradykinin Dose Response Experiments.....   | 150 |
| v.   | Testing of mAB2s.....   | 152 |
| C.   | Results.....  | 157 |
| i.   | Bradykinin Dose Response Experiments.....   | 157 |
| ii.  | Test for mAB2 Agonist Activity.....   | 157 |
| iii. | Test for mAB2 Antagonist Activity...  | 160 |
| D.   | Discussion.....   | 163 |
| i.   | Related Literature.....   | 163 |
| ii.  | Experimental Protocol.....  | 164 |
| iii. | Possible Problems with the PC12 Bioassay and Future Experiments.....                            | 166 |

|     |   |     |
|-----|---|-----|
| a.  | mAB2 Concentration.....                       | 166 |
| b.  | Receptor Accessibility.....                   | 168 |
| c.  | Cooperativity Between<br>Immunoglobulins..... | 171 |
| d.  | Time.....                                     | 171 |
| vi. | Summary.....                                  | 172 |
| V.  | Global Summary.....                           | 173 |
| VI. | Bibliography.....                             | 177 |